



8 March 2021

OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")

Grant of Options

Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance testing, announces that the Group's Remuneration Committee and the Board has, on 5 March 2021, approved the grant of 200,000 Options over ordinary shares of 4 pence each in the Company to Simon Douglas, Non-Executive Chairman, under the Company's Third Unapproved Option Scheme.

The Options were granted with an exercise price of 89 pence each, being the closing middle market price on 4 March 2021. The Options will vest over three years, one third vesting on each anniversary of the grant date. Following the grant, these Options represent Simon Douglas' only interest in the Company.

The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.

Contacts:

Omega Diagnostics Group PLC

Colin King, Chief Executive
Kieron Harbinson, Group Finance Director

www.omegadiagnostics.com

Via Walbrook PR

finnCap Ltd

Geoff Nash/ Teddy Whiley (Corporate Finance)
Alice Lane (ECM)

Tel: 020 7220 0500

Walbrook PR Limited

Paul McManus
Lianne Cawthorne

Tel: 020 7933 8780 or omega@walbrookpr.com

Mob: 07980 541 893

Mob: 07584 391 303

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014		
1 Details of the person discharging managerial responsibilities/person closely associated		
a.	Name	Simon Douglas
2 Reason for notification		
a.	Position/Status	Non-Executive Chairman

b.	Initial notification/ Amendment	Initial Notification								
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor									
a.	Name	Omega Diagnostics Group Plc								
b.	LEI	2138007U9P4BTZTYIR92								
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted									
a.	Description of the financial instrument, type of instrument	200,000 Options over Ordinary Shares of 4 pence each were granted with an exercise price of 89 pence each. The Options will vest over three years, one third vesting on each anniversary of the grant date.								
	Identification Code	ISIN: GB00B1VCP282								
b.	Nature of the transaction	Granting of Share Options								
c.	Price(s) and volume(s)	<table><tr><td>Price(s)</td><td>Volume(s)</td><td></td></tr><tr><td>89p</td><td>200,000</td><td></td></tr></table>			Price(s)	Volume(s)		89p	200,000	
Price(s)	Volume(s)									
89p	200,000									
d.	Aggregated information	As above.								
e.	Date of the transaction	5 March 2021								
f.	Place of the transaction	London Stock Exchange								